Foghorn Therapeutics Inc.NASDAQ:FHTX
- LAST PRICE7.5200
- TODAY'S CHANGE (%)-0.3800 (-4.8101%)
- Bid / Lots5.0000/ 1
- Ask / Lots9.5000/ 10
- Open / Previous Close7.8400 / 7.9000
- Day Range
- 52 Week Range
- Volume79,541
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FHTX |
|---|---|---|
| 09:32 ET | 476 | 7.84 |
| 09:35 ET | 100 | 7.72 |
| 09:39 ET | 938 | 7.8 |
| 09:44 ET | 1441 | 7.8 |
| 09:51 ET | 100 | 7.805 |
| 09:53 ET | 100 | 7.805 |
| 10:02 ET | 728 | 7.805 |
| 10:04 ET | 100 | 7.805 |
| 10:13 ET | 100 | 7.81 |
| 10:15 ET | 100 | 7.81 |
| 10:18 ET | 1400 | 7.835 |
| 10:20 ET | 158 | 7.835 |
| 10:22 ET | 600 | 7.835 |
| 10:27 ET | 728 | 7.74 |
| 10:29 ET | 300 | 7.65 |
| 10:31 ET | 100 | 7.66 |
| 10:33 ET | 417 | 7.705 |
| 10:38 ET | 100 | 7.65 |
| 10:40 ET | 300 | 7.7 |
| 10:45 ET | 636 | 7.74 |
| 10:47 ET | 100 | 7.71 |
| 10:51 ET | 183 | 7.7745 |
| 10:58 ET | 100 | 7.85 |
| 11:02 ET | 435 | 7.8351 |
| 11:05 ET | 400 | 7.79 |
| 11:20 ET | 100 | 7.67 |
| 11:21 ET | 200 | 7.67 |
| 11:23 ET | 230 | 7.68 |
| 11:25 ET | 400 | 7.725 |
| 11:30 ET | 200 | 7.735 |
| 11:38 ET | 100 | 7.735 |
| 11:39 ET | 100 | 7.79 |
| 11:48 ET | 100 | 7.815 |
| 11:52 ET | 100 | 7.835 |
| 11:54 ET | 521 | 7.715 |
| 12:14 ET | 337 | 7.81 |
| 12:17 ET | 2663 | 7.805 |
| 12:19 ET | 500 | 7.78 |
| 12:24 ET | 200 | 7.8 |
| 12:28 ET | 100 | 7.75 |
| 12:30 ET | 130 | 7.84 |
| 12:33 ET | 200 | 7.78 |
| 12:35 ET | 6569 | 7.835 |
| 12:39 ET | 277 | 7.77 |
| 01:09 ET | 363 | 7.68 |
| 01:24 ET | 100 | 7.58 |
| 01:27 ET | 100 | 7.59 |
| 01:38 ET | 100 | 7.59 |
| 01:42 ET | 275 | 7.6 |
| 01:44 ET | 100 | 7.73 |
| 01:47 ET | 100 | 7.6 |
| 01:49 ET | 200 | 7.64 |
| 01:51 ET | 100 | 7.66 |
| 01:54 ET | 121 | 7.72 |
| 02:12 ET | 100 | 7.66 |
| 02:16 ET | 100 | 7.65 |
| 02:18 ET | 200 | 7.64 |
| 02:30 ET | 100 | 7.58 |
| 02:32 ET | 639 | 7.58 |
| 02:43 ET | 100 | 7.55 |
| 02:48 ET | 100 | 7.59 |
| 02:56 ET | 105 | 7.57 |
| 02:57 ET | 100 | 7.59 |
| 03:03 ET | 399 | 7.64 |
| 03:06 ET | 100 | 7.59 |
| 03:14 ET | 300 | 7.585 |
| 03:17 ET | 921 | 7.61 |
| 03:21 ET | 524 | 7.56 |
| 03:28 ET | 112 | 7.56 |
| 03:33 ET | 100 | 7.57 |
| 03:35 ET | 100 | 7.54 |
| 03:37 ET | 526 | 7.58 |
| 03:42 ET | 100 | 7.51 |
| 03:48 ET | 600 | 7.59 |
| 03:50 ET | 200 | 7.53 |
| 03:51 ET | 100 | 7.555 |
| 03:53 ET | 426 | 7.52 |
| 03:55 ET | 100 | 7.51 |
| 03:57 ET | 1285 | 7.51 |
| 04:00 ET | 19482 | 7.52 |
Nov 12, 2024
Foghorn Therapeutics to Participate in Three Upcoming Investor Conferences, from 7:54AM ET on Tuesday Nov 12, 2024 by Dow Jones
7:54AM ET on Tuesday Nov 12, 2024 by Dow Jones
Nov 4, 2024
Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update, from 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
4:05PM ET on Monday Nov 04, 2024 by Dow JonesPress Release: Foghorn Therapeutics Provides Third Quarter 2024 Financial and Corporate Update, from 4:05PM ET on Monday Nov 04, 2024 by Dow Jones
4:05PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Foghorn Therapeutics Inc. | 435.9M | -3.9x | --- |
Tango Therapeutics Inc | 421.1M | -3.3x | --- |
OmniAb Inc | 471.3M | -6.1x | --- |
Silence Therapeutics PLC | 327.1M | -5.3x | --- |
Silence Therapeutics PLC | 327.1M | -6.1x | --- |
Cartesian Therapeutics Inc | 479.6M | -0.5x | --- |
Company Information
Foghorn Therapeutics Inc. is a clinical-stage biotechnology company engaged in developing medicines that modulate gene expression through selectively targeting the chromatin regulatory system for therapeutic intervention in oncology. Its Gene Traffic Control platform gives an integrated, mechanistic understanding of how the various components of the chromatin regulatory system interact, allowing to identify, validate and potentially drug targets within the system. The Company’s Traffic Control platform discovers and develops drugs in oncology and other therapeutic areas, including virology, autoimmune disease and neurology. The Company is developing FHD-286, a selective, allosteric ATPase inhibitor and which is evaluating two separate Phase I studies in metastatic uveal melanoma and relapsed and/or refractory acute myeloid leukemia, and myelodysplastic syndrome. It is also developing FHD-909 a highly potent, allosteric and orally available small molecule.
Contact Information
- Headquarters
- 500 Technology Square, Suite 700CAMBRIDGE, MA, United States 02139
- Phone
- 617-586-3100
- Fax
- 302-655-5049
Executives
- President, Chief Executive Officer, Director
- Adrian Gottschalk
- Chief Financial Officer
- Kristian Humer
- Chief People Officer
- Carlos Costa
- Chief Scientific Officer
- Steven Bellon
- Chief Strategy and Business Operations Officer
- Fanny Cavalie
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $435.9M |
|---|---|
Revenue (TTM) | $25.5M |
Shares Outstanding | 55.6M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 3.11 |
EPS | $-1.91 |
Book Value | $-1.83 |
P/E Ratio | -3.9x |
Price/Sales (TTM) | 17.1 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -408.14% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
